X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (7747) 7747
Publication (653) 653
Book Review (589) 589
Magazine Article (18) 18
Book Chapter (16) 16
Conference Proceeding (14) 14
Book / eBook (2) 2
Data Set (2) 2
Dissertation (2) 2
Newspaper Article (1) 1
Paper (1) 1
Trade Publication Article (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (7076) 7076
sulfones - pharmacology (4101) 4101
humans (3936) 3936
animals (3847) 3847
male (3028) 3028
sildenafil citrate (1789) 1789
pharmacology & pharmacy (1785) 1785
rats (1726) 1726
sulfones (1718) 1718
piperazines - pharmacology (1383) 1383
female (1372) 1372
mice (1251) 1251
sildenafil (978) 978
sulfones - chemistry (858) 858
purines (847) 847
sulfones - therapeutic use (836) 836
adult (771) 771
chemistry, medicinal (769) 769
middle aged (754) 754
dose-response relationship, drug (747) 747
phosphodiesterase inhibitors - pharmacology (696) 696
purines - pharmacology (651) 651
biochemistry & molecular biology (638) 638
piperazines - therapeutic use (621) 621
rats, sprague-dawley (614) 614
structure-activity relationship (608) 608
expression (545) 545
erectile dysfunction (510) 510
aged (486) 486
enzyme inhibitors - pharmacology (486) 486
sulfones - chemical synthesis (486) 486
sulfones - administration & dosage (478) 478
guanidines - pharmacology (476) 476
nitriles - pharmacology (467) 467
time factors (466) 466
cells, cultured (463) 463
analysis (458) 458
cell line, tumor (446) 446
abridged index medicus (444) 444
nitric-oxide (442) 442
rats, wistar (427) 427
activation (424) 424
erectile dysfunction - drug therapy (423) 423
lactones - pharmacology (416) 416
in vitro techniques (407) 407
disease models, animal (406) 406
sulfones - adverse effects (386) 386
apoptosis (376) 376
cell biology (376) 376
oncology (372) 372
in-vitro (367) 367
vasodilator agents - pharmacology (362) 362
cardiac & cardiovascular systems (360) 360
cell line (355) 355
inhibition (349) 349
research (349) 349
celecoxib (341) 341
nf-kappa b - metabolism (341) 341
nitric oxide (340) 340
apoptosis - drug effects (333) 333
nonsteroidal antiinflammatory drugs (333) 333
sodium-hydrogen exchangers - antagonists & inhibitors (326) 326
urology & nephrology (325) 325
molecular structure (323) 323
nf-kappa b - antagonists & inhibitors (323) 323
administration, oral (320) 320
cyclooxygenase inhibitors - pharmacology (319) 319
kinetics (318) 318
rofecoxib (318) 318
sulfonamides - pharmacology (313) 313
cancer (312) 312
physiology (310) 310
inhibitors (309) 309
signal transduction - drug effects (309) 309
inflammation (307) 307
cells (305) 305
antineoplastic agents - pharmacology (303) 303
article (302) 302
piperazines - administration & dosage (298) 298
cyclooxygenase 2 (295) 295
phosphodiesterase inhibitors - therapeutic use (292) 292
toxicology (289) 289
chemistry, organic (288) 288
imidazoles - pharmacology (284) 284
lactones - adverse effects (284) 284
signal transduction (284) 284
vardenafil dihydrochloride (282) 282
treatment outcome (279) 279
sulfones - pharmacokinetics (275) 275
purines - therapeutic use (273) 273
rabbits (269) 269
double-blind method (266) 266
models, molecular (266) 266
cyclooxygenase 2 inhibitors (261) 261
sulfones - metabolism (256) 256
cell proliferation - drug effects (254) 254
piperazines - adverse effects (253) 253
physiological aspects (251) 251
drug interactions (247) 247
blood pressure - drug effects (245) 245
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (7394) 7394
German (99) 99
French (62) 62
Japanese (59) 59
Chinese (58) 58
Russian (35) 35
Italian (24) 24
Polish (16) 16
Spanish (15) 15
Dutch (4) 4
Portuguese (3) 3
Swedish (3) 3
Ukrainian (3) 3
Danish (2) 2
Norwegian (2) 2
Romanian (2) 2
Bosnian (1) 1
Bulgarian (1) 1
Czech (1) 1
Finnish (1) 1
Turkish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


European Journal of Pharmacology, ISSN 0014-2999, 2007, Volume 572, Issue 1, pp. 12 - 22
Pulmonary fibroblast to myofibroblast conversion is a pathophysiological feature of idiopathic pulmonary fibrosis and COPD. This conversion is induced by... 
TGF-β | Sildenafil | Lung fibroblast | Fibrosis | Phosphodiesterase | lung fibroblast | CELLS | CYCLIC-NUCLEOTIDE PHOSPHODIESTERASES | PROLIFERATION | sildenafil | CARDIAC FIBROBLASTS | TGF-beta | GROWTH-FACTOR-BETA | DISEASE | NITRIC-OXIDE | PHARMACOLOGY & PHARMACY | fibrosis | phosphodiesterase | DIFFERENTIATION | IDIOPATHIC PULMONARY-FIBROSIS | EXPRESSION | Enzyme Activators - pharmacology | Immunohistochemistry | Cyclic GMP - pharmacology | Humans | Actins - metabolism | Lung - cytology | Natriuretic Peptide, Brain - pharmacology | Sulfones - pharmacology | Quinoxalines - pharmacology | Sildenafil Citrate | Nitroso Compounds - pharmacology | Isoenzymes - metabolism | Oxadiazoles - pharmacology | Benzamides - pharmacology | Nitric Oxide Donors - pharmacology | Myocytes, Smooth Muscle - drug effects | Myocytes, Smooth Muscle - cytology | Myocytes, Smooth Muscle - metabolism | Fibroblasts - metabolism | Dinoprostone - pharmacology | Purines - pharmacology | Cells, Cultured | Transforming Growth Factor beta - physiology | Phosphodiesterase Inhibitors - pharmacology | Guanylate Cyclase - metabolism | Soluble Guanylyl Cyclase | Piperazines - pharmacology | Blotting, Western | Drug Synergism | Transforming Growth Factor beta - pharmacology | Cell Differentiation - drug effects | Fibroblasts - drug effects | Benzoates - pharmacology | Fibroblasts - cytology | Pyridines - pharmacology | Receptors, Cytoplasmic and Nuclear - metabolism | Index Medicus
Journal Article
The Journal of Sexual Medicine, ISSN 1743-6095, 12/2012, Volume 9, Issue 12, pp. 3028 - 3040
The efficacy of phosphodiesterase type 5 inhibitors (PDE5i) in treating lower urinary tract symptoms is supported by the extremely high expression and activity... 
Bladder | PDE5 | Vardenafil | PHOSPHODIESTERASE-5 INHIBITORS | FUNCTIONAL-ACTIVITY | NITRIC-OXIDE SYNTHASE | DETRUSOR SMOOTH-MUSCLE | CGMP-BINDING | LOWER URINARY-TRACT | BENIGN PROSTATIC HYPERPLASIA | IN-VITRO | UROLOGY & NEPHROLOGY | SEXUAL DYSFUNCTION | EXPRESSION | Estradiol - blood | Estrogens - pharmacology | Nitriles - pharmacology | Aromatase Inhibitors - pharmacology | Male | Nitroprusside - pharmacology | RNA, Messenger - metabolism | Sulfones - pharmacology | Testosterone - pharmacology | Muscle, Smooth - drug effects | Female | Nitric Oxide Donors - pharmacology | Testosterone - blood | Phosphodiesterase 5 Inhibitors - pharmacology | Cyclic Nucleotide Phosphodiesterases, Type 5 - metabolism | Progesterone - pharmacology | Estradiol - pharmacology | Gene Expression | Triazines - pharmacology | Ovariectomy | Urinary Bladder - metabolism | Progestins - pharmacology | Rats | Imidazoles - pharmacology | Piperazines - pharmacology | Rats, Sprague-Dawley | Triazoles - pharmacology | Animals | Androgens - pharmacology | Sex Factors | Vardenafil Dihydrochloride | Cyclic Nucleotide Phosphodiesterases, Type 5 - genetics | Urinary Bladder - drug effects | Muscle Relaxation - drug effects | Testosterone | Enzymes | Genes | Phenols | Sodium nitroferricyanide | Cyanides | Estradiol | Cyclic guanylic acid | Index Medicus
Journal Article
Respiratory Research, ISSN 1465-9921, 12/2011, Volume 12, Issue 1, pp. 1 - 8
The development of bronchial hyperreactivity (BHR) subsequent to precapillary pulmonary hypertension (PHT) was prevented by acting on the major signalling... 
Medicine & Public Health | Pneumology/Respiratory System | PARENCHYMAL MECHANICS | LUNG | METHACHOLINE-INDUCED BRONCHOCONSTRICTION | AIRWAY | THERAPY | VASOACTIVE-INTESTINAL-PEPTIDE | RESPIRATORY SYSTEM | ARTERIAL-HYPERTENSION | INHALATION | NITRIC-OXIDE | VIP | Antihypertensive Agents - pharmacology | Tetrazoles - pharmacology | Airway Resistance - drug effects | Iloprost - pharmacology | Bronchial Provocation Tests | Antihypertensive Agents - administration & dosage | Hypertension, Pulmonary - physiopathology | Male | Endothelins - metabolism | Sulfones - pharmacology | Lung Volume Measurements | Sildenafil Citrate | Time Factors | Vasoactive Intestinal Peptide - pharmacology | Bronchoconstriction - drug effects | Bronchial Hyperreactivity - physiopathology | Bronchial Hyperreactivity - metabolism | Blood Pressure - drug effects | Hypertension, Pulmonary - drug therapy | Lung - metabolism | Phosphodiesterase 5 Inhibitors - pharmacology | Endothelin Receptor Antagonists | Disease Models, Animal | Bronchial Hyperreactivity - etiology | Prostaglandins I - metabolism | Bronchial Hyperreactivity - therapy | Infusion Pumps, Implantable | Vasodilator Agents - pharmacology | Administration, Oral | Purines - pharmacology | Receptors, Endothelin - metabolism | Infusions, Parenteral | Rats | Hypertension, Pulmonary - metabolism | Lung - physiopathology | Piperazines - pharmacology | Rats, Sprague-Dawley | Animals | Analysis of Variance | Signal Transduction - drug effects | Lung - drug effects | Pyridines - pharmacology | Lung - blood supply | Nitric Oxide - metabolism | Vasodilator Agents - administration & dosage | Hypertension, Pulmonary - complications | Bronchi | Physiological aspects | Development and progression | Respiratory agents | Research | Drug therapy | Health aspects | Pulmonary hypertension | Prevention | Nitric oxide | Index Medicus
Journal Article
The Journal of Sexual Medicine, ISSN 1743-6095, 04/2013, Volume 10, Issue 4, pp. 960 - 971
Prevalence of erectile dysfunction (ED) increases progressively with aging, but the ED pathophysiology at its early stages is still poorly investigated. This... 
Erectile Dysfunction | Antioxidant Therapy | Oxidative Stress | Corpus Cavernosum | Apocynin | Superoxide Dismutase | STIMULATOR BAY 41-2272 | HUMAN CORPUS CAVERNOSUM | RELAXATION | DIABETIC-RATS | PHOSPHODIESTERASE TYPE-5 INHIBITORS | SOLUBLE GUANYLATE-CYCLASE | SMOOTH-MUSCLE | CARDIOVASCULAR-DISEASE | UROLOGY & NEPHROLOGY | ENDOGENOUS NITRIC-OXIDE | Blood Pressure | Free Radical Scavengers - pharmacology | Cyclic GMP - pharmacology | Up-Regulation | Electric Stimulation | Membrane Glycoproteins - metabolism | NADPH Oxidases - metabolism | Male | Nitroprusside - pharmacology | RNA, Messenger - metabolism | Sulfones - pharmacology | Penile Erection | Sildenafil Citrate | Cyclic GMP - analogs & derivatives | Acetophenones - pharmacology | NADPH Oxidases - genetics | Phosphodiesterase 5 Inhibitors - pharmacology | Superoxide Dismutase - metabolism | Pyrazoles - pharmacology | Superoxide Dismutase - pharmacology | Vasodilator Agents - pharmacology | Acetylcholine - pharmacology | Purines - pharmacology | Down-Regulation | Enzyme Inhibitors - pharmacology | Rats | Muscle Relaxation | NADPH Oxidase 2 | Piperazines - pharmacology | Erectile Dysfunction - metabolism | Membrane Glycoproteins - genetics | Animals | Aging - physiology | Cyclic GMP - metabolism | Endothelium, Vascular - metabolism | Nitric Oxide Synthase - metabolism | Pyridines - pharmacology | Superoxide Dismutase-1 | Prevention | Oxidases | Antioxidants | Impotence | Nitric oxide | Sodium nitroferricyanide | Superoxide | Index Medicus
Journal Article
Journal Article
Journal Article
FASEB Journal, ISSN 0892-6638, 03/2006, Volume 20, Issue 3, pp. 542 - 544
It is widely believed that the potencies of nonsteroid anti-inflammatory drugs ( NSAIDs) as inhibitors of cyclooxygenase ( COX) are influenced by protein... 
SITE | MECHANISM | BIOCHEMISTRY & MOLECULAR BIOLOGY | nonsteroid anti-inflammatory drugs | coxibs | PROSTAGLANDIN H-2 SYNTHASE | CELL BIOLOGY | CYCLO-OXYGENASE-2 | THERAPY | FLUID | NONSTEROIDAL ANTIINFLAMMATORY DRUGS | BIOLOGY | prostaglandins | SELECTIVITY | Organic Chemicals - cerebrospinal fluid | Humans | Naproxen - pharmacology | Synovial Fluid - metabolism | Pyrazoles - cerebrospinal fluid | Sodium Salicylate - pharmacology | Lactones - pharmacology | Aspirin - cerebrospinal fluid | Cell Line - drug effects | Calcium - physiology | Pyrazoles - blood | Organic Chemicals - pharmacology | Dinoprostone - cerebrospinal fluid | Diclofenac - cerebrospinal fluid | Aspirin - pharmacology | Sulfones - cerebrospinal fluid | Aspirin - blood | Thiazines - blood | Sulfonamides - pharmacology | Indomethacin - cerebrospinal fluid | Indomethacin - pharmacology | Cyclooxygenase 1 - drug effects | Cyclooxygenase Inhibitors - adverse effects | Cyclooxygenase Inhibitors - blood | Diclofenac - pharmacology | Thiazoles - blood | Thromboxane A2 - blood | Cerebrospinal Fluid Proteins - pharmacology | Dinoprostone - biosynthesis | Lactones - cerebrospinal fluid | Blood Platelets - enzymology | Cyclooxygenase 2 Inhibitors - cerebrospinal fluid | Sodium Salicylate - cerebrospinal fluid | Sulfones - pharmacology | Blood Proteins - pharmacology | Cyclooxygenase 2 Inhibitors - adverse effects | Sulfonamides - blood | Lactones - blood | Naproxen - cerebrospinal fluid | Sodium Salicylate - blood | Thiazines - pharmacology | Cyclooxygenase 2 Inhibitors - blood | Cyclooxygenase Inhibitors - cerebrospinal fluid | Blood Platelets - drug effects | Sulfones - blood | Organic Chemicals - blood | Ionophores - pharmacology | Pyrazoles - pharmacology | Sulfonamides - cerebrospinal fluid | Cyclooxygenase 2 Inhibitors - pharmacology | Thiazoles - cerebrospinal fluid | Celecoxib | Diclofenac - blood | Dinoprostone - blood | Naproxen - blood | Organ Specificity | Calcimycin - pharmacology | Cyclooxygenase Inhibitors - pharmacology | Indomethacin - blood | Protein Binding | Thiazines - cerebrospinal fluid | Thiazoles - pharmacology | Index Medicus
Journal Article
European Journal of Pharmacology, ISSN 0014-2999, 2005, Volume 517, Issue 3, pp. 224 - 231
Hypercholesterolaemia promotes erectile dysfunction through increased superoxide formation and negation of nitric oxide (NO) bioactivity in cavernosal tissue.... 
Erectile dysfunction | Superoxide | NADPH oxidase | Cholesterol | RISK-FACTORS | ENDOTHELIUM-DEPENDENT RELAXATION | ATHEROSCLEROSIS | PULMONARY-ARTERY | erectile dysfunction | SMOOTH-MUSCLE | IN-VITRO | CORPUS CAVERNOSUM | CYCLIC-GMP | cholesterol | PHARMACOLOGY & PHARMACY | superoxide | CGMP PHOSPHODIESTERASE INHIBITOR | Uncoupling Agents - pharmacology | Nitric Oxide Synthase - antagonists & inhibitors | Male | Nitroprusside - pharmacology | Dose-Response Relationship, Drug | Quinoxalines - pharmacology | Sildenafil Citrate | Penis - drug effects | Purines | Oxadiazoles - pharmacology | Acetophenones - pharmacology | Rotenone - pharmacology | Superoxides - metabolism | Nitric Oxide Donors - pharmacology | Sulfones | Xanthine Oxidase - antagonists & inhibitors | NG-Nitroarginine Methyl Ester - pharmacology | Rabbits | NADPH Oxidases - antagonists & inhibitors | Enzyme Inhibitors - pharmacology | Penis - physiopathology | Phosphodiesterase Inhibitors - pharmacology | Onium Compounds - pharmacology | Piperazines - pharmacology | Carbachol - pharmacology | Animals | Cyclic GMP - metabolism | Penis - metabolism | Allopurinol - pharmacology | Hypercholesterolemia - physiopathology | Muscle Relaxation - drug effects | In Vitro Techniques | Oxidases | Hypercholesterolemia | Impotence | Analysis | Nitric oxide | Sodium nitroferricyanide | Sildenafil | Guanylate cyclase | Index Medicus
Journal Article
Molecular Cancer Therapeutics, ISSN 1535-7163, 07/2007, Volume 6, Issue 7, pp. 2012 - 2021
With the development of targeted therapeutics, especially for small-molecule inhibitors, it is important to understand whether the observed in vivo efficacy... 
kinase inhibitor | Pharmacodynamics | pazopanib | angiogenesis | VEGF | TARGET | ONCOLOGY | FACTOR RECEPTORS | EXPRESSION | CANCER | TUMORS | RENAL-CELL CARCINOMA | ENDOTHELIAL GROWTH-FACTOR | Pyrimidines - blood | Humans | Fibroblast Growth Factor 2 - pharmacology | Antineoplastic Agents - administration & dosage | Indazoles - administration & dosage | Sulfones - pharmacology | Neovascularization, Pathologic - pathology | Phosphotyrosine - metabolism | Dose-Response Relationship, Drug | Sulfonamides - blood | Inhibitory Concentration 50 | Receptors, Vascular Endothelial Growth Factor - antagonists & inhibitors | Female | Antineoplastic Agents - pharmacokinetics | Antineoplastic Agents - pharmacology | Cornea - pathology | Phosphorylation - drug effects | Sulfones - blood | Vascular Endothelial Growth Factor A - pharmacology | Protein Kinase Inhibitors - pharmacokinetics | Pyrimidines - administration & dosage | Pyrimidines - pharmacology | Sulfones - pharmacokinetics | Sulfonamides - pharmacology | Protein Kinase Inhibitors - blood | Sulfonamides - pharmacokinetics | Indazoles - pharmacology | Protein Kinase Inhibitors - administration & dosage | Indazoles - blood | Animals | Indazoles - pharmacokinetics | Cell-Free System | Mice, Nude | Antineoplastic Agents - blood | Cell Line, Tumor | Pyrimidines - pharmacokinetics | Mice | Protein Kinase Inhibitors - pharmacology | Sulfonamides - administration & dosage | Sulfones - administration & dosage | Index Medicus
Journal Article